Animal data supports J&J's Alzheimer's vaccine

J&J's Alzheimer's research group at Janssen has found positive signs for bapineuzumab, its late-stage Alzheimer's therapeutic vaccine. In a study using mice, researchers found that those who were inoculated performed a simple task more effectively, which could mean the vax was successful at stopping amyloid plaque from binding with neurons. Story

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.